Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ronald F, Siebenaler"'
Autor:
Jessica J. Waninger, Tyler S. Beyett, Varun V. Gadkari, Ronald F. Siebenaler, Carson Kenum, Sunita Shankar, Brandon T. Ruotolo, Arul M. Chinnaiyan, John J.G. Tesmer
Publikováno v:
Biochemistry and Biophysics Reports, Vol 29, Iss , Pp 101191- (2022)
Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with small molecule drugs has been chal
Externí odkaz:
https://doaj.org/article/5afdc55c4e9a499fb8675d06a6b666e1
Autor:
Sunita Shankar, Jean Ching-Yi Tien, Ronald F. Siebenaler, Seema Chugh, Vijaya L. Dommeti, Sylvia Zelenka-Wang, Xiao-Ming Wang, Ingrid J. Apel, Jessica Waninger, Sanjana Eyunni, Alice Xu, Malay Mody, Andrew Goodrum, Yuping Zhang, John J. Tesmer, Rahul Mannan, Xuhong Cao, Pankaj Vats, Sethuramasundaram Pitchiaya, Stephanie J. Ellison, Jiaqi Shi, Chandan Kumar-Sinha, Howard C. Crawford, Arul M. Chinnaiyan
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Argonaute 2 (AGO2) binds RAS and is required for cellular transformation. Here, the authors establish a KRAS-driven mouse model of pancreatic cancer with conditional loss of AGO2 and show that the early phase of neoplastic lesion initiation is depend
Externí odkaz:
https://doaj.org/article/4879439f815846169a9d5e62cae6d7c2
Autor:
Yashar S. Niknafs, Sumin Han, Teng Ma, Corey Speers, Chao Zhang, Kari Wilder-Romans, Matthew K. Iyer, Sethuramasundaram Pitchiaya, Rohit Malik, Yasuyuki Hosono, John R. Prensner, Anton Poliakov, Udit Singhal, Lanbo Xiao, Steven Kregel, Ronald F. Siebenaler, Shuang G. Zhao, Michael Uhl, Alexander Gawronski, Daniel F. Hayes, Lori J. Pierce, Xuhong Cao, Colin Collins, Rolf Backofen, Cenk S. Sahinalp, James M. Rae, Arul M. Chinnaiyan, Felix Y. Feng
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
LncRNAs have been associated with cancer. Here, the authors carry out a systematic review of lncRNAs in breast cancer and show that DSCAM-AS1is highly expressed in oestrogen receptor positive tumours and enhances cancer through an interaction with hn
Externí odkaz:
https://doaj.org/article/683cca27103c413a96704a7bec3d8d79
Autor:
Ronald F, Siebenaler, Seema, Chugh, Jessica J, Waninger, Vijaya L, Dommeti, Carson, Kenum, Malay, Mody, Anudeeta, Gautam, Nidhi, Patel, Alec, Chu, Pushpinder, Bawa, Jennifer, Hon, Richard D, Smith, Heather, Carlson, Xuhong, Cao, John J G, Tesmer, Sunita, Shankar, Arul M, Chinnaiyan
Publikováno v:
PNAS nexus. 1(3)
Activating mutations in RAS GTPases drive nearly 30% of all human cancers. Our prior work described an essential role for Argonaute 2 (AGO2), of the RNA-induced silencing complex, in mutant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3a0db7859f58a658fbd6a0c12517a0b0
https://pubmed.ncbi.nlm.nih.gov/35923912
https://pubmed.ncbi.nlm.nih.gov/35923912
Autor:
Ronald F. Siebenaler, Jean Ching-Yi Tien, Vijaya L. Dommeti, Rahul Mannan, Stephanie J. Ellison, Sethuramasundaram Pitchiaya, Xuhong Cao, Seema Chugh, Howard C. Crawford, Ingrid J. Apel, Jessica Waninger, Chandan Kumar-Sinha, Andrew Goodrum, Sanjana Eyunni, Sylvia Zelenka-Wang, Pankaj Vats, Yuping Zhang, Malay Mody, Jiaqi Shi, Xiaoming Wang, Alice Xu, Sunita Shankar, John J.G. Tesmer, Arul M. Chinnaiyan
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Both KRAS and EGFR are essential mediators of pancreatic cancer development and interact with Argonaute 2 (AGO2) to perturb its function. Here, in a mouse model of mutant KRAS-driven pancreatic cancer, loss of AGO2 allows precursor lesion (PanIN) for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9077dc44bf831609cf6ec27f23f5ed5e
http://europepmc.org/articles/PMC7272436
http://europepmc.org/articles/PMC7272436
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c10b05b6c41d502334361d825fcd4998
https://doi.org/10.1096/fasebj.2019.33.1_supplement.509.10
https://doi.org/10.1096/fasebj.2019.33.1_supplement.509.10
Autor:
Vijaya L. Dommeti, Howard C. Crawford, Jiaqi Shi, Andrew Goodrum, Sylvia Zelenka-Wang, Ingrid J. Apel, Sanjana Eyunni, Ronald F. Siebenaler, Sethuramsundaram Pitchiaya, Sunita Shankar, Yuping Zhang, Xiaoming Wang, Javed Siddiqui, Jean Ching-Yi Tien, Arul M. Chinnaiyan, Kristin M. Juckette, Seema Chugh, Jessica Waninger, Chandan Kumar-Sinha, Xuhong Cao
Publikováno v:
Cancer Research. 80:2577-2577
KRAS mutations drive over 30% of all cancers and 90% of pancreatic cancer. To investigate additional potential modulators of RAS-mediated oncogenesis, we previously performed a screen for direct interactors of RAS in a panel of cancer cell lines and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2180b97e040cda4c094f6bf92231ecf7
https://doi.org/10.1158/1538-7445.am2020-2577
https://doi.org/10.1158/1538-7445.am2020-2577
Autor:
Ronald F. Siebenaler, Jean Tien, Heather A. Carlson, Vijaya L. Dommeti, Richard D. Smith, Arul M. Chinnaiyan, Jessica Waninger, Malay Mody, Chandan Kumar-Sinha, John J.G. Tesmer, Tyler S. Beyett, Sunita Shankar
Publikováno v:
Molecular Cancer Research. 18:B39-B39
KRAS is one of three members of the RAS family of small GTPases, and nearly one third of all human cancers harbor mutations in the KRAS gene. These mutations lead to a constitutively active GTP-bound form of KRAS that results in aberrant activation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a1a40e041355c09c2ed231a8193cb14
https://doi.org/10.1158/1557-3125.ras18-b39
https://doi.org/10.1158/1557-3125.ras18-b39
Autor:
Ronald F. Siebenaler, Sylvia Zelenka-Wang, Malay Mody, Vijaya L. Dommeti, Sunita Shankar, Arul M. Chinnaiyan, Jean C. Tien, Jessica Waninger, Chandan Kumar-Sinha, Seema Chugh
Publikováno v:
Molecular Cancer Research. 18:A21-A21
The RAS gene family is among the most commonly mutated genes within cancer, but little progress has been made in successfully targeting RAS mutations. Targeting binding partners of mutated RAS, however, presents a promising alternative therapeutic st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2f48cb59e93cc24d6939fa80a805025
https://doi.org/10.1158/1557-3125.ras18-a21
https://doi.org/10.1158/1557-3125.ras18-a21
Autor:
Jiaqi Shi, Andrew Goodrum, Vijaya L. Dommeti, John J.G. Tesmer, Alice Xu, Kristin M. Juckette, Sunita Shankar, Arul M. Chinnaiyan, Sanjana Eyunni, Xiaoming Wang, Malay Mody, Ronald F. Siebenaler, Yuping Zhang, Javed Siddiqui, Sylvia Zelenka-Wang, Grace Tsaloff, Jean Ching-Yi Tien, Xuhong Cao, Ingrid J. Apel, Richard D. Smith, Jessica Waninger, Chandan Kumar-Sinha, Lisha Wang, Seema Chugh, Heather A. Carlson
Publikováno v:
Molecular Cancer Research. 18:A20-A20
In 2016, we identified a direct interaction between RAS and Argonaute 2 (AGO2), a key mediator of RNA-mediated gene silencing that is required for KRAS-driven oncogenesis using pancreatic and lung cancer cell line models. Recently, we employed the ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52de412d176232202b9c263194ac6208
https://doi.org/10.1158/1557-3125.ras18-a20
https://doi.org/10.1158/1557-3125.ras18-a20